Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Oncology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(16)00106-6PMID 27155741PMCID PMC5524539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study)

  2015cited by this paper
• Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.

  2015cited by this paper
• Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

  2015cited by this paper
• Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

  2014cited by this paper
• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

  2014cited by this paper
• Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

  2014cited by this paper
• First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

  2014cited by this paper
• Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

  2014cited by this paper
• PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

  2013cited by this paper
• Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

  2013cited by this paper
• Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

  2013cited by this paper
• Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

  2013cited by this paper
• Activating ESR1 mutations in hormone-resistant metastatic breast cancer

  2013cited by this paper
• SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC).

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

  2011cited by this paper
• A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

  2011cited by this paper
• Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

  2010cited by this paper
• PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

  2010cited by this paper
• New Strategies in Estrogen Receptor–Positive Breast Cancer

  2010cited by this paper
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

  2009cited by this paper
• PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

  2009cited by this paper
• Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women

  2007cited by this paper
• Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

  2003cited by this paper

• A Decade of Innovation in Breast Cancer (2015–2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives

  2026influential citation
• Targeting the PI3K/AKT/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions

  2026cites this paper
• Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer: a systematic review and meta-analysis

  2025cites this paper
• Targeting CDK2 and other novel cell cycle targets for breast cancer therapy

  2025cites this paper
• PI3K/AKT/mTOR axis in vascular malformations: from molecular insights to targeted clinical trials

  2025cites this paper
• Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer

  2025cites this paper
• An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer

  2025influential citation
• Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review

  2025cites this paper
• Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.

  2025cites this paper
• Epigenetic Therapy in Hormone Positive Breast Cancer: The Role of PIK3CA

  2025cites this paper
• Current landscape and recent developments of PI3K/AKT/mTOR targeted inhibitors for breast carcinoma.

  2025cites this paper
• GASPS: A Multi-Omics Framework for Defining Genomic Aberration-Driven Signatures and Predicting Patient Outcomes in Lung Cancer

  2025cites this paper
• New thieno[2,3-d]pyrimidinone-based derivatives: Design, synthesis, biological potential, and in silico studies against breast cancer

  2025cites this paper
• Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives

  2025cites this paper
• The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions

  2025cites this paper
• Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care.

  2024cites this paper
• PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment.

  2024cites this paper
• Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: mechanisms and therapeutic potential.

  2024cites this paper
• Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment

  2024cites this paper
• Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis

  2024influential citation
• Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma

  2024cites this paper
• Rational Design of a Novel 6H-Benzo[c]chromen Series as Selective PI3Kα Inhibitors.

  2024cites this paper
• Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

  2024cites this paper
• Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

  2024cites this paper
• Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs

  2024cites this paper
• PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.

  2024cites this paper
• Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.

  2024cites this paper
• Public neoantigens in breast cancer immunotherapy (Review)

  2024cites this paper
• Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion

  2024cites this paper
• Navigating the Complexity of PI3K/AKT Pathway in HER-2 Negative Breast Cancer: Biomarkers and Beyond.

  2024cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

  2024cites this paper
• Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

  2024cites this paper
• Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs

  2024cites this paper
• Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells

  2024cites this paper
• A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

  2024cites this paper
• Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

  2024cites this paper
• Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

  2024cites this paper
• Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

  2023cites this paper
• Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

  2023cites this paper
• Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer

  2023cites this paper
• CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

  2023cites this paper
• Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

  2023cites this paper
• The emerging role of PI3K inhibitors for solid tumour treatment and beyond

  2023cites this paper
• Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies

  2023cites this paper
• Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

  2023cites this paper
• Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis.

  2023cites this paper
• Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus

  2023cites this paper
• The molecular genetics of PI3K/PTEN/AKT/mTOR pathway in the malformations of cortical development

  2023cites this paper
• Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis

  2023cites this paper
• Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer

  2023cites this paper
• Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

  2023cites this paper
• ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

  2022cites this paper
• PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

  2022cites this paper
• Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

  2022cites this paper
• Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.

  2022cites this paper
• PI3K Isoform Immunotherapy for Solid Tumours.

  2022cites this paper
• Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• [Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer].

  2022cites this paper
• Current Molecular Combination Therapies Used for the Treatment of Breast Cancer

  2022cites this paper
• mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma

  2022cites this paper
• Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

  2022cites this paper
• Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

  2022cites this paper
• CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

  2022cites this paper
• PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist

  2022cites this paper
• TfOH-catalyzed regioselective N2-alkylation of indazoles with diazo compounds.

  2022cites this paper
• A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry

  2022cites this paper
• PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

  2022cites this paper
• Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment

  2022cites this paper
• Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

  2022cites this paper
• Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer

  2022cites this paper
• Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases

  2022cites this paper
• PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

  2022cites this paper
• Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

  2022cites this paper
• Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.

  2022cites this paper
• The Applications of Plasma Cell-free DNA in Cancer Detection: Implications in the Management of Breast Cancer Patients.

  2022cites this paper
• Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.

  2021cites this paper
• AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B.

  2021cites this paper
• Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice

  2021cites this paper
• Current State of Breast Cancer Diagnosis, Treatment, and Theranostics

  2021influential citation
• Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer

  2021cites this paper
• Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

  2021influential citation
• Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis

  2021cites this paper
• Breast Cancer Treatments: Updates and New Challenges

  2021cites this paper
• Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?

  2021cites this paper
• Deciphering the signaling network of breast cancer improves drug sensitivity prediction.

  2021cites this paper
• PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

  2021cites this paper
• PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Cancer: Overview for Oncology Clinical Practice

  2021cites this paper
• TCRM_A_251668 193..207

  2021cites this paper
• The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients

  2021cites this paper
• Clinical application of circulating tumor DNA in breast cancer

  2021cites this paper
• Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

  2021cites this paper
• PI3K INHIBITION IN BREAST CANCER: IDENTIFYING AND OVERCOMING DIFFERENT FLAVORS OF RESISTANCE.

  2021cites this paper
• RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

  2021cites this paper
• Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression

  2021cites this paper
• Multiple strategies for the treatment of invasive breast carcinoma: a comprehensive prospective.

  2021cites this paper
• Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors

  2021cites this paper
• Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.

  2021cites this paper
• Orthogonal Regulation of Nucleophilic and Electrophilic Sites in Pd-Catalyzed Regiodivergent Couplings between Indazoles and Isoprene.

  2021cites this paper